Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2007

Evotec, Boehringer Ingelheim, and IMP Form Alzheimer’s Disease Target Discovery Collaboration

  • Evotec, Boehringer  Ingelheim, and the Research Institute of Molecular Pathology in Vienna (IMP) will jointly identify novel targets as potential points of intervention in the treatment of Alzheimer’s disease (AD).

    Evotec scientists together with the IMP will apply validated disease models to identify novel AD targets. Based on these models, Boehringer Ingelheim will select and further validate target candidates for its in-house drug discovery program.

    The contract includes an option for Evotec to support Boehringer Ingelheim (BI) in the target validation process. Evotec could then be eligible for milestone payments of up to Euro 20 million plus royalties.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »